<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ojrdrt</journal-id><journal-title-group><journal-title xml:lang="ru">Онкологический журнал: лучевая диагностика, лучевая терапия</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of oncology: diagnostic radiology and radiotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7593</issn><issn pub-type="epub">2713-167X</issn><publisher><publisher-name>НЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37174/2587-7593-2024-7-3-62-71</article-id><article-id custom-type="elpub" pub-id-type="custom">ojrdrt-379</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КОМБИНИРОВАННЫЕ МЕТОДЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>COMBINED METHODS OF DIAGNOSTICS AND TREATMENT</subject></subj-group></article-categories><title-group><article-title>Регионарная внутриартериальная химиотерапия в комплексном лечении местнораспространенного рака слизистой оболочки полости рта</article-title><trans-title-group xml:lang="en"><trans-title>Intra-Arterial Chemotherapy for Locally Advanced Oral Cavity Cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3275-2886</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Выжигина</surname><given-names>Б. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Vyzhigina</surname><given-names>B. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Выжигина Белла Борисовна —  аспирант ФГБУ НИМЦ им. Н.Н. Блохина; врач-онколог отделения опухолей головы и шеи ГКБ им. С.С. Юдина</p><p>115478 Москва, Каширское шоссе, 24</p></bio><bio xml:lang="en"><p>Bella B. Vyzhigina</p><p>4 Kashirskoe Shosse, Moscow, 115478</p></bio><email xlink:type="simple">vyz.bella@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9132-3416</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кропотов</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kropotov</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кропотов Михаил Алексеевич — д.м.н., заведующий хирургическим отделением опухолей головы и шеи</p><p>115478 Москва, Каширское шоссе, 24</p></bio><bio xml:lang="en"><p>Michael A. Kropotov</p><p>4 Kashirskoe Shosse, Moscow, 115478</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7185-7165</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Долгушин</surname><given-names>Б. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Dolgushin</surname><given-names>B. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Долгушин Борис Иванович — директор НИИ КиЭР НМИЦ онкологии им. Н.Н. Блохина Минздрава России, д.м.н., профессор, академик РАН</p><p>115478 Москва, Каширское шоссе, 24</p></bio><bio xml:lang="en"><p>Boris I. Dolgushin</p><p>4 Kashirskoe Shosse, Moscow, 115478</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2793-5597</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сафаров</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Safarov</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сафаров Давид Афатдинович — к.м.н., врач-онколог хирургического отделения опухолей головы и шеи</p><p>115478 Москва, Каширское шоссе, 24</p></bio><bio xml:lang="en"><p>David A. Safarov</p><p>4 Kashirskoe Shosse, Moscow, 115478</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4587-4153</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Погребняков</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pogrebnyakov</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Погребняков Игорь Вячеславович — к.м.н., заведующий отделением-врач по рентгенэндоваскулярным диагностике и лечению</p><p>115478 Москва, Каширское шоссе, 24</p></bio><bio xml:lang="en"><p>Igor V. Pogrebnyakov</p><p>4 Kashirskoe Shosse, Moscow, 115478</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6835-5567</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алиева</surname><given-names>С. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Alieva</surname><given-names>S. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алиева Севил Багатуровна — профессор, д.м.н., врач-радиотерапевт</p><p>115478 Москва, Каширское шоссе, 24</p></bio><bio xml:lang="en"><p>Sevil B. Alieva</p><p>4 Kashirskoe Shosse, Moscow, 115478</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.N. Blokhin National Medical Research Center of Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>19</day><month>09</month><year>2024</year></pub-date><volume>7</volume><issue>3</issue><fpage>62</fpage><lpage>71</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Выжигина Б.Б., Кропотов М.А., Долгушин Б.И., Сафаров Д.А., Погребняков И.В., Алиева С.Б., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Выжигина Б.Б., Кропотов М.А., Долгушин Б.И., Сафаров Д.А., Погребняков И.В., Алиева С.Б.</copyright-holder><copyright-holder xml:lang="en">Vyzhigina B.B., Kropotov M.A., Dolgushin B.I., Safarov D.A., Pogrebnyakov I.V., Alieva S.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.oncoradjournal.ru/jour/article/view/379">https://www.oncoradjournal.ru/jour/article/view/379</self-uri><abstract><sec><title>Введение</title><p>Введение: Стандартным методом лечения местнораспространенного рака слизистой оболочки полости рта является хирургическое вмешательство с последующей химиолучевой терапией. Кроме очевидных преимуществ, такое лечение несет в себе риски серьезных функциональных и эстетических нарушений, длительного периода реабилитации. С другой стороны, стан дартные режимы химиолучевого лечения не позволяют добиться адекватных результатов. Регионарная внутриартериальная химиотерапия является перспективным методом лечения местнораспространенного рака слизистой оболочки полости рта, позволяющим воздействовать на опухоль с минимизацией системных побочных реакций и сохранить функцию органа, а, следовательно, качество жизни пациентов.</p></sec><sec><title>Цель</title><p>Цель: Сравнить результаты лечения больных с местнораспространенным раком слизистой оболочки полости рта с применением индукционной регионарной внутриартериальной химиотерапии (РВАХТ) в составе химиолучевого лечения с результатами комплексного лечения с хирургическим вмешательством на первом этапе.</p></sec><sec><title>Материал и методы</title><p>Материал и методы: В исследование включено 62 пациентов, проходивших лечение в 2017–2023 гг. с местнораспространенным раком слизистой оболочки полости рта. Из них 23 пациентам была проведена индукционная химиотерапия по схеме DCF с внутриартериальным введением цисплатина и доцетаксела. Во второй группе 39 пациентам проведено комбинированное лечение с хирургическим лечением на первом этапе. Первичной конечной точкой исследования была общая и без рецидивная выживаемость. Вторичные конечные точки — частота объективного ответа, токсичность лечения и выявление прогностических факторов в группе внутриартериальной регионарной химиотерапии.</p></sec><sec><title>Результаты</title><p>Результаты: Продолжительность наблюдения за пациентами в группе РВАХТ составила 20,37 (ДИ 13,23–25,87) месяца и в группе хирургического лечения — 32,6 (ДИ 17,1– 43,6) месяцев. 1-летняя общая выживаемость (ОВ) в группе РВАХТ составила 84,1 %, а в группе хирургического лечения — 69,2 % (p = 0,582). Выживаемость без прогрессирования (ВБП) в течение одного года в группе РВАХТ составила 77,9 %, и в группе хирургического лечения 62,5 % (p = 0,944). При подгрупповом анализе было выявлено улучшение 1-летней ОВ у пациентов с обработкой одного регионарного бассейна (p = 0,005). 1-летняя ОВ после индукционной химиотерапии первичной опухоли при полном, частичном ответе и стабилизации составили 90,9, 67,5 и 0 % (p &lt; 0,001) соответственно. 1-летняя ВБП при полном, частичном ответе и стабилизации составили 80, 76,2 и 0 % (p &lt; 0,000) соответственно.</p></sec><sec><title>Выводы</title><p>Выводы: Регионарная внутриартериальная химиотерапия в плане химиолучевого лечения демонстрирует равнозначную эффективность по результатам общей и безрецидивной выживаемости у пациентов с местнораспространенными резекта бельными опухолями слизистой оболочки полости рта при сравнении с группой хирургического лечения в плане комплексного лечения.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction: The standard treatment for locally advanced oral cavity cancer is surgery with followed by chemoradiotherapy Surgical treatment carries serious external and aesthetic risks and a long period of rehabilitation. On the other hand, standard chemoradiation treatment does not achieve adequate results. Intra-arterial chemotherapy is a promising treatment option. This method allows targeting the tumor to be while minimizing systemic factors and organ preservation, and the quality of life of the patients.</p></sec><sec><title>Purpose</title><p>Purpose: To compare the results of treatment of patients with locally advanced oral cancer using induction intra-arterial chemotherapy and surgical treatment at the first step.</p></sec><sec><title>Material and methods</title><p>Material and methods: 62 patients were treated from 2017 to 2023 with locally advanced oral cancer. 23 patients underwent induction chemotherapy according to the DCF regimen with intra-arterial administration of cisplatin and docetaxel. In the second group, 39 patients underwent combined treatment with surgical treatment at the first step. The primary endpoint of the study was overall and disease-free survival. Secondary — objective response, treatment toxicity and the occurrence of prognostic factors in the intra-arterial chemotherapy group.</p></sec><sec><title>Results</title><p>Results: The duration of follow-up of patients in the intra-arterial group was 20.37 (CI 13.23–25.87) and in the surgery group 32.6 (CI 17.1–43.6) months. 1-year overall survival (OS) in the intra-arterial group and in the surgical group was 84.1 % and 69.2 % (p = 0.582), relapse-free survival (RFS) — 77.9 % and 62.5 % (p = 0.944). A subgroup analysis revealed an improvement in OS in patients treated with one arterial basin (p = 0.005). 1-year OS aﬅer induction chemotherapy for complete response, partial response, and stabilization were 90.9, 67.5, and 0 % (p &lt; 0.001), respectively. 1-year RFS for complete response, partial response, and stabilization were 80, 76.2, and 0 % (p &lt; 0.000), respectively.</p></sec><sec><title>Conclusions</title><p>Conclusions: Intra-arterial chemotherapy has equivalent eﬃcacy in terms of survival in patients with locally advanced tumors, oral cavity conclusion is indicated.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>плоскоклеточный рак</kwd><kwd>аденокистозный рак</kwd><kwd>рак слизистой оболочки полости рта</kwd><kwd>рак языка</kwd><kwd>индукционная химиотерапия</kwd><kwd>внутриартериальная химиотерапия</kwd><kwd>хирургия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>squamous cell carcinoma</kwd><kwd>adenoid cystic carcinoma</kwd><kwd>oral cavity cancer</kwd><kwd>tongue cancer</kwd><kwd>induction chemotherapy</kwd><kwd>intra-arterial chemotherapy</kwd><kwd>surgery</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bray F, Laversanne M, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2024;74(3):229-63 https://doi.org/10.3322/caac.21834</mixed-citation><mixed-citation xml:lang="en">Bray F, Laversanne M, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2024;74(3):229-63 https://doi.org/10.3322/caac.21834</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн АД, Старинский ВВ, Шахзадова АО и др. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Москва, 2022.</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Starinsky VV, Shakhzadova AO (Eds.). Malignant neoplasms in Russia in 2021 (morbidity and mortality). — Moscow, 2022.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн АД, Старинский ВВ, Шахзадова АО и др. Состояние онкологической помощи населению России в 2021 году. Москва, 2022.</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Starinsky VV, Shakhzadova AO (Eds.). The state of cancer care for the population of Russia in 2022. — Moscow, 2022.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Romano A, et al. Noninvasive imaging methods to improve the diagnosis of oral carcinoma and its precursors: state of the art and proposal of a three-step diagnostic process. Can cers. 2021;13:2864. https://doi.org/10.3390/cancers13122864</mixed-citation><mixed-citation xml:lang="en">Romano A, et al. Noninvasive imaging methods to improve the diagnosis of oral carcinoma and its precursors: state of the art and proposal of a three-step diagnostic process. Can cers. 2021;13:2864. https://doi.org/10.3390/cancers13122864</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010;15:994-1001. https://doi.org/10.1634/theoncologist.2009-0289</mixed-citation><mixed-citation xml:lang="en">Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010;15:994-1001. https://doi.org/10.1634/theoncologist.2009-0289</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mroueh R, Haapaniemi A, Grenman R, et al. Improved out comes with oral tongue squamous cell carcinoma in Finland. Head Neck 2017;39(7):1306-12. https://doi.org/10.1002/hed.24744</mixed-citation><mixed-citation xml:lang="en">Mroueh R, Haapaniemi A, Grenman R, et al. Improved out comes with oral tongue squamous cell carcinoma in Finland. Head Neck 2017;39(7):1306-12. https://doi.org/10.1002/hed.24744</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sher DJ, Thotakura V, Balboni TA, et al. Treatment of oral cavity squamous cell carcinoma with adjuvant or deﬁnitive intensity-modulated radiation therapy. Int J Radiat Oncol. 2011;81(4):215-22. https://doi.org/10.1016/j.ijrobp.2011.07.005</mixed-citation><mixed-citation xml:lang="en">Sher DJ, Thotakura V, Balboni TA, et al. Treatment of oral cavity squamous cell carcinoma with adjuvant or deﬁnitive intensity-modulated radiation therapy. Int J Radiat Oncol. 2011;81(4):215-22. https://doi.org/10.1016/j.ijrobp.2011.07.005</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Iyer NG, Tan DSW, Tan VK, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastat ic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121(10):1599-607. https://doi.org/10.1002/cncr.29251</mixed-citation><mixed-citation xml:lang="en">Iyer NG, Tan DSW, Tan VK, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastat ic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121(10):1599-607. https://doi.org/10.1002/cncr.29251</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gore SM, Crombie AK, Batstone MD, et al. Concurrent chemoradiotherapy compared with surgery and adjuvant radiotherapy for oral cavity squamous cell carcinoma. Head Neck. 2015;37(4):518-23. https://doi.org/10.1002/hed.23626.</mixed-citation><mixed-citation xml:lang="en">Gore SM, Crombie AK, Batstone MD, et al. Concurrent chemoradiotherapy compared with surgery and adjuvant radiotherapy for oral cavity squamous cell carcinoma. Head Neck. 2015;37(4):518-23. https://doi.org/10.1002/hed.23626.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Alzahrani R, Obaid A, Alshehri A, et al. Locally Advanced Oral Cavity Cancers: What Is The Optimal Care? Cancer Control. 2020;27(1). https://doi.org/10.1177/1073274820920727</mixed-citation><mixed-citation xml:lang="en">Alzahrani R, Obaid A, Alshehri A, et al. Locally Advanced Oral Cavity Cancers: What Is The Optimal Care? Cancer Control. 2020;27(1). https://doi.org/10.1177/1073274820920727</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol. 2003;21(2):327-33. https://doi.org/10.1200/JCO.2003.06.146.</mixed-citation><mixed-citation xml:lang="en">Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol. 2003;21(2):327-33. https://doi.org/10.1200/JCO.2003.06.146.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bossi P, Lo Vullo S, Guzzo M, et al. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Ann Oncol. 2014;25(2):462-6. https://doi.org/10.1093/annonc/mdt555.</mixed-citation><mixed-citation xml:lang="en">Bossi P, Lo Vullo S, Guzzo M, et al. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Ann Oncol. 2014;25(2):462-6. https://doi.org/10.1093/annonc/mdt555.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zhong L, Zhang C, Ren G, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and ﬂuorouracil followed by surgery versus up-front surgery in local ly advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31(6):744-51. https://doi.org/10.1200/JCO.2012.43.8820.</mixed-citation><mixed-citation xml:lang="en">Zhong L, Zhang C, Ren G, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and ﬂuorouracil followed by surgery versus up-front surgery in local ly advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31(6):744-51. https://doi.org/10.1200/JCO.2012.43.8820.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zhong L, Zhang C, Ju W, Wang L, et al. Phase III trial of docetaxel cisplatin 5-ﬂuorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic out come. Cancer Commun (Lond). 2021;41(3):279-83. https://doi.org/10.1002/cac2.12136</mixed-citation><mixed-citation xml:lang="en">Zhong L, Zhang C, Ju W, Wang L, et al. Phase III trial of docetaxel cisplatin 5-ﬂuorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic out come. Cancer Commun (Lond). 2021;41(3):279-83. https://doi.org/10.1002/cac2.12136</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Haddad R, O’Neill A, Rabinowits G, et al. Induction chemo therapy followed by concurrent chemoradiotherapy (se quential chemoradiotherapy) versus concurrent chemo radiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet On col. 2013;14(3):257-64. https://doi.org/10.1016/S1470-2045(13)70011-1</mixed-citation><mixed-citation xml:lang="en">Haddad R, O’Neill A, Rabinowits G, et al. Induction chemo therapy followed by concurrent chemoradiotherapy (se quential chemoradiotherapy) versus concurrent chemo radiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet On col. 2013;14(3):257-64. https://doi.org/10.1016/S1470-2045(13)70011-1</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ghi M, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer, a phase II-III trial. Ann Oncol. 2017;28(9):2206-12. https://doi.org/10.1093/annonc/mdx299.</mixed-citation><mixed-citation xml:lang="en">Ghi M, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer, a phase II-III trial. Ann Oncol. 2017;28(9):2206-12. https://doi.org/10.1093/annonc/mdx299.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mukai Y, Hayashi Y, Koike I, et al. Impact of superselective intra-arterial and systemic chemoradiotherapy for gingival carcinoma; analysis of treatment outcomes and prognostic factors. BMC Cancer. 2020;26;20(1):1154. https://doi.org/10.1186/s12885-020-07638-y.</mixed-citation><mixed-citation xml:lang="en">Mukai Y, Hayashi Y, Koike I, et al. Impact of superselective intra-arterial and systemic chemoradiotherapy for gingival carcinoma; analysis of treatment outcomes and prognostic factors. BMC Cancer. 2020;26;20(1):1154. https://doi.org/10.1186/s12885-020-07638-y.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Xiang L, Zheng Y, Ren P, et al. 5-Fluorouracil combined with cisplatin via arterial induction for advanced T-stage na sopharyngeal carcinoma: A 10-year outcome of a phase I/II study Front Oncol. eCollection 2022. Front Oncol. 2022;27:12:868070. https://doi.org/10.3389/fonc.2022.868070.</mixed-citation><mixed-citation xml:lang="en">Xiang L, Zheng Y, Ren P, et al. 5-Fluorouracil combined with cisplatin via arterial induction for advanced T-stage na sopharyngeal carcinoma: A 10-year outcome of a phase I/II study Front Oncol. eCollection 2022. Front Oncol. 2022;27:12:868070. https://doi.org/10.3389/fonc.2022.868070.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kovács AF, et al. Response to intraarterial induction chemo therapy: A prognostic parameter in oral and oropharyngeal cancer. Head &amp; Neck, 2006;28(8):678-88. https://doi.org/10.1002/hed.20388</mixed-citation><mixed-citation xml:lang="en">Kovács AF, et al. Response to intraarterial induction chemo therapy: A prognostic parameter in oral and oropharyngeal cancer. Head &amp; Neck, 2006;28(8):678-88. https://doi.org/10.1002/hed.20388</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Akihiro Homma, Rikiya Onimaru, Kazuto Matsuura, K et. al. Intra-arterial chemoradiotherapy for head and neck cancer. pn J Clin Oncol. 2016;46(1):4-12. https://doi.org/10.1093/jjco/hyv151</mixed-citation><mixed-citation xml:lang="en">Akihiro Homma, Rikiya Onimaru, Kazuto Matsuura, K et. al. Intra-arterial chemoradiotherapy for head and neck cancer. pn J Clin Oncol. 2016;46(1):4-12. https://doi.org/10.1093/jjco/hyv151</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Mitsudo K, Koizumi T, Iida M, et al. Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: analysis of therapeutic results in 112 cases. Radiother Oncol. 2014;111:306-10. https://doi.org/10.1016/j.radonc.2014.03.005</mixed-citation><mixed-citation xml:lang="en">Mitsudo K, Koizumi T, Iida M, et al. Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: analysis of therapeutic results in 112 cases. Radiother Oncol. 2014;111:306-10. https://doi.org/10.1016/j.radonc.2014.03.005</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Homma A, Onimaru R, Robbins, et al. Intra-arterial chemo radiotherapy for head and neck cancer. Jpn J Clin Oncol. 2016;46(01):4-12. https://doi.org/10.1093/jjco/hyv151</mixed-citation><mixed-citation xml:lang="en">Homma A, Onimaru R, Robbins, et al. Intra-arterial chemo radiotherapy for head and neck cancer. Jpn J Clin Oncol. 2016;46(01):4-12. https://doi.org/10.1093/jjco/hyv151</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kobayashi W, Kukobota K, Itо R, et al. Can Superselective Intra-Arterial Chemoradiotherapy Replace Surgery Followed by Radiation for Advanced Cancer of the Tongue and Floor of the Mouth? 2016;74(6):1248-54. https://doi.org/10.1016/j.joms.2016.01.007</mixed-citation><mixed-citation xml:lang="en">Kobayashi W, Kukobota K, Itо R, et al. Can Superselective Intra-Arterial Chemoradiotherapy Replace Surgery Followed by Radiation for Advanced Cancer of the Tongue and Floor of the Mouth? 2016;74(6):1248-54. https://doi.org/10.1016/j.joms.2016.01.007</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Minamiyama S, Mitsudo K, Hayashi Y, et al. Retrograde superselective intra-arterial chemotherapy and daily concur rent radiotherapy for T2 4N0 tongue cancer: control of occult neck metastasis. Oral Surg Oral Med Oral Pathol Oral Radiol 2017;124:16-23. https://doi.org/10.1016/j.oooo.2017.02.004</mixed-citation><mixed-citation xml:lang="en">Minamiyama S, Mitsudo K, Hayashi Y, et al. Retrograde superselective intra-arterial chemotherapy and daily concur rent radiotherapy for T2 4N0 tongue cancer: control of occult neck metastasis. Oral Surg Oral Med Oral Pathol Oral Radiol 2017;124:16-23. https://doi.org/10.1016/j.oooo.2017.02.004</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kamran M., Wallace AN, Adewumi A. Interventional Man agement of Head and Neck Tumors. Semin Intervent Radiol. 2020;37(2):157-65. https://doi.org/10.1055/s-0040-1709157</mixed-citation><mixed-citation xml:lang="en">Kamran M., Wallace AN, Adewumi A. Interventional Man agement of Head and Neck Tumors. Semin Intervent Radiol. 2020;37(2):157-65. https://doi.org/10.1055/s-0040-1709157</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y, Kang EJ, Keam B, et al. Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Local ly Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01). Cancer Res Treat. 2022;54(1):109-17. https://doi.org/10.4143/crt.2020.1329</mixed-citation><mixed-citation xml:lang="en">Lee Y, Kang EJ, Keam B, et al. Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Local ly Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01). Cancer Res Treat. 2022;54(1):109-17. https://doi.org/10.4143/crt.2020.1329</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Романов ИС, Яковлева ЛП. Вопросы лечения рака полости рта. Фарматека. 2013;8:21-5.</mixed-citation><mixed-citation xml:lang="en">Romanov IS, Yakovleva LP. Treatment of oral cancer. Phar mateka. 2013;8:21-5.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Byers RM, El-Naggar AK, Lee YY, et al. Can we detect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue? Head Neck. 1998; 20:138 44. https://doi.org/10.1002/(sici)1097-0347(199803)20:23.0.co;2-3</mixed-citation><mixed-citation xml:lang="en">Byers RM, El-Naggar AK, Lee YY, et al. Can we detect or pre dict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue? Head Neck. 1998; 20:138 44. https://doi.org/10.1002/(sici)1097-0347(199803)20:23.0.co;2-3</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kaya S, Yilmaz T, Gürsel B, et al. The value of elective neck dissection in treatment of cancer of the tongue. Am J Otolaryngol. 2001;22:59-64. https://doi.org/10.1053/ajot.2001.20681</mixed-citation><mixed-citation xml:lang="en">Kaya S, Yilmaz T, Gürsel B, et al. The value of elective neck dissection in treatment of cancer of the tongue. Am J Otolar yngol. 2001;22:59-64. https://doi.org/10.1053/ajot.2001.20681</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Sparano A, Weinstein G, Chalian A, et al. Multivariate pre dictors of occult neck metastasis in early oral tongue cancer. Otolaryngol Head Neck Surg. 2004;131:472-6. https://doi.org/10.1016/j.otohns.2004.04.008</mixed-citation><mixed-citation xml:lang="en">Sparano A, Weinstein G, Chalian A, et al. Multivariate pre dictors of occult neck metastasis in early oral tongue cancer. Otolaryngol Head Neck Surg. 2004;131:472-6. https://doi.org/10.1016/j.otohns.2004.04.008</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Singh A, Huryn JM, Kronstadt KL, et al. Osteoradionecrosis of the jaw: A mini review. Front Oral Health. 2022;3:980786. https://doi.org/10.3389/froh.2022.980786</mixed-citation><mixed-citation xml:lang="en">Singh A, Huryn JM, Kronstadt KL, et al. Osteoradionecrosis of the jaw: A mini review. Front Oral Health. 2022;3:980786. https://doi.org/10.3389/froh.2022.980786</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Chen JA, Wang CC, Wong YK, et al. Osteoradionecrosis of mandible bone in patients with oral cancer-associated factors and treatment outcomes. Head Neck. 2016;38:762-8. https://doi.org/10.1002/hed.23949</mixed-citation><mixed-citation xml:lang="en">Chen JA, Wang CC, Wong YK, et al. Osteoradionecrosis of mandible bone in patients with oral cancer-associated fac tors and treatment outcomes. Head Neck. 2016;38:762-8. https://doi.org/10.1002/hed.23949</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Studer G, Bredell M, Studer S, et al. Risk proﬁle for osteoradionecrosis of the mandible in the IMRT era. Strahlenther Onkol. 2016;192:32-9 https://doi.org/10.1007/s00066-015-0875-6</mixed-citation><mixed-citation xml:lang="en">Studer G, Bredell M, Studer S, et al. Risk proﬁle for osteor adionecrosis of the mandible in the IMRT era. Strahlenther Onkol. 2016;192:32-9 https://doi.org/10.1007/s00066-015-0875-6</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
